Fierce BioBiotech
AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win
21 Apr 20260 views
Summary
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 code.
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has served up a third phase 3 win, offering further evidence the Big Pharma may have cracked the anti-IL-33 code.